Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

G. Daniele, D. Lorusso, G. Scambia, S.C. Cecere, M.O. Nicoletto, E. Breda, N. Colombo, G. Artioli, L. Cannella, G. Lo Re, F. Raspagliesi, G. Maltese, V. Salutari, G. Ferrandina, S. Greggi, A. Baldoni, A. Bergamini, M.C. Piccirillo, G. Tognon, I. FlorianiS. Signoriello, F. Perrone, S. Pignata

Research output: Contribution to journalArticlepeer-review

Cite this